SCHEDULE: Republic Digital's Stake in Sonnet BioTherapeutics Falls Below 5% Following Share Increase

Sentiment:

Beneficial Ownership Disclosure


Republic Digital Opportunistic Digital Assets Master Fund, Ltd. and Joseph Naggar's beneficial ownership in Sonnet BioTherapeutics Holdings, Inc. decreased to 4.2% after an increase in the issuer's outstanding common stock.

Capital raiseThe issuer completed a private placement offering.Certain outstanding warrants were exercised.These events collectively increased the number of outstanding Common Stock shares by 2,931,437, from 3,332,728 to 6,264,165 shares.

Summary

  • Republic Digital Opportunistic Digital Assets Master Fund, Ltd. and Joseph Naggar jointly reported beneficial ownership of 260,000 shares of Sonnet BioTherapeutics Holdings, Inc. Common Stock.
  • This represents 4.2% of the class, calculated based on 6,264,165 shares outstanding as of July 18, 2025.
  • The reporting persons' beneficial ownership exceeded 5% (specifically 5.0%+) as of July 14, 2025, based on 3,332,728 shares then-outstanding, which triggered the requirement for this Schedule 13G filing.
  • As of July 18, 2025, their beneficial ownership fell below 5% due to the closing of a private placement offering and the exercise of certain outstanding warrants, which increased the total outstanding shares by 2,931,437 to 6,264,165 shares.
  • Republic Digital Opportunistic Digital Assets Master Fund, Ltd. is organized under the laws of the Cayman Islands, and Joseph Naggar is a U.S. citizen.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of a change in beneficial ownership percentage due to share dilution from a capital raise. While the capital raise itself is generally positive for the company, the dilution for the reporting persons is a neutral to slightly negative outcome for their stake.

Positives

  • Sonnet BioTherapeutics Holdings, Inc. successfully completed a private placement offering and had warrants exercised, leading to an increase in outstanding shares and likely capital infusion for the company.

Negatives

  • The reporting persons' percentage of beneficial ownership in Sonnet BioTherapeutics Holdings, Inc. was diluted from over 5% to 4.2% due to the increase in outstanding shares.

Risks

  • No specific risks related to the company's operations or financial health were detailed in this ownership disclosure filing.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

  • Shareholders: Existing shareholders, including the reporting persons, experienced dilution of their percentage ownership due to the increase in outstanding shares from the private placement and warrant exercises.

Key Dates

DateDescription
07/14/2025Date of event which required filing of this statement; reporting persons' beneficial ownership exceeded 5% of then-outstanding shares.
07/18/2025Date when the issuer's current report on Form 8-K was filed, reporting 6,264,165 shares of Common Stock outstanding after a private placement and warrant exercises, causing reporting persons' ownership to fall below 5%.
07/25/2025Date of signing of the Schedule 13G filing and the Joint Filing Agreement.

Keywords

Sonnet BioTherapeutics Holdings Inc., Republic Digital Opportunistic Digital Assets Master Fund, Joseph Naggar, Schedule 13G, Beneficial Ownership, Common Stock, Dilution, Private Placement, Warrant Exercise, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.